The Pharmacy Times® Schizophrenia Resource Center is a comprehensive resource for clinical news and expert insights on treatments for schizophrenia.
September 4th 2025
FDA approves a new extended-release suspension formulation of risperidone for schizophrenia, expanding treatment options for patients.
The Pharmacist’s Role: Opioid-related Risks With a Psychiatric Drug
Pharmacists dispensing Lybalvi should understand that potentially life-threatening consequences can occur if opioids are taken concurrently.
Read More
Study: Subcutaneous Injectable Risperidone Improves Outcomes for Certain Patients With Schizophrenia
November 16th 2021The trial randomized patients to receive TV-46000 once monthly, TV-46000 once every 2 months, or placebo, and found that patients had improved outcomes on TV-46000 regardless of dosing schedule.
Read More